Race influences warfarin dose changes associated with genetic factors.
about
STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATIONDoes low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study.Warfarin pharmacogenomics and African ancestry.Integrating electronic health record genotype and phenotype datasets to transform patient careRace-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysisTamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.Bioprinting and Organ-on-Chip Applications Towards Personalized Medicine for Bone Diseases.Warfarin Pharmacogenomics in Diverse Populations.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose.Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.Genetic determinants of variability in warfarin response after the dose-titration phase.Pharmacogenetics in Cardiovascular Medicine.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage.Benefit of pre-emptive pharmacogenetic information on clinical outcome.Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine.The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacementUser considerations in assessing pharmacogenomic tests and their clinical support toolsCreating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients
P2860
Q33557032-33A8DF99-C46D-4D5B-A22C-1C499AB8903BQ35810550-D1799571-2311-45E0-9355-B95AEDE3220DQ35884246-B95B12E9-792A-46DA-8B4C-FED698203961Q36599112-8B4F4B42-A8D3-4BB5-8269-753353972C34Q36717256-26520CE5-B345-4C70-A582-AF9973E39C7AQ36742224-929BA4F7-C8E5-4DD1-9CDF-7E40742262CFQ37091133-E816F424-C218-4868-BED6-1A10879F88D2Q37473370-0C747295-66D8-46B4-AFE2-28CE5AAE2E8FQ38673908-D2AEA78C-66E6-490B-84DE-C8B8BDF4F201Q38696567-7DCA8D8B-54B7-4EB7-A38A-DC619942EABDQ38750444-CF5A888A-1DC6-4924-A5AD-F856C2A22EADQ38796447-E100181B-1D5B-4DFF-AE35-F44058C91223Q39262868-67B46926-37E2-4E43-B54C-0420E1866F7DQ40083909-DFB08308-F7EA-4791-9EAB-C8F1D40A5B24Q40132047-6D2FFE72-CA53-4CBF-A72B-7573AA292BE1Q40629929-0475DFE3-20F3-4E7D-8E7B-106949D3D26BQ43113299-FCDCE7CC-13A0-4066-9A89-6D25C4171EA7Q47130405-72CB4351-D3C5-45BA-AF17-67CBE8976C45Q47345423-F38338C7-73A2-4B63-BF19-A4F2309945C3Q47728750-4596209A-241C-4155-B63D-F5FF55AEBAADQ47920228-F469C750-8177-4F5F-9EFD-5A49BB00957AQ49378467-F278C336-1F1B-4ECF-8585-5E52B07FA6B2Q49612005-CE95095B-3717-47F0-9D27-B9ADAC5FF413Q55379283-8E948493-FBEB-4F2C-801B-26844B7D42FDQ57500191-FFD2D757-DF2C-4EF5-82AF-DAB458FB3D60Q57646588-B27D466A-0665-4664-BA62-6BE628A1EA0AQ58558658-1C238A49-9CD6-4D90-8E63-2AE4FB477604
P2860
Race influences warfarin dose changes associated with genetic factors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Race influences warfarin dose changes associated with genetic factors.
@ast
Race influences warfarin dose changes associated with genetic factors.
@en
type
label
Race influences warfarin dose changes associated with genetic factors.
@ast
Race influences warfarin dose changes associated with genetic factors.
@en
prefLabel
Race influences warfarin dose changes associated with genetic factors.
@ast
Race influences warfarin dose changes associated with genetic factors.
@en
P2093
P2860
P1433
P1476
Race influences warfarin dose changes associated with genetic factors
@en
P2093
Aditi Shendre
Charles E Hill
Nianjun Liu
Nita A Limdi
T Mark Beasley
Todd M Brown
P2860
P304
P356
10.1182/BLOOD-2015-02-627042
P407
P577
2015-05-29T00:00:00Z